(Q39679346)

English

Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission

scientific article published on 14 July 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Plasmodium vivax

0 references

0 references

1 reference

based on heuristic

inferred from title

Jetsumon Sattabongkot

3

object named as

Jetsumon Sattabongkot

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Takafumi Tsuboi

object named as

Takafumi Tsuboi

4

0 references

Shigeto Yoshida

2

object named as

Shigeto Yoshida

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Robert E Sinden

5

object named as

Robert E Sinden

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

author name string

Andrew M Blagborough

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

14 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

6014-6020

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

"Baculophage": a new tool for protein display

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of Bombyx mori

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Baculovirus virions displaying Plasmodium berghei circumsporozoite protein protect mice against malaria sporozoite infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Quantitative Plasmodium sporozoite neutralization assay (TSNA).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Transmission blocking malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Current developments in malaria transmission-blocking vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Molecular interactions between Plasmodium and its insect vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Malaria transmission-blocking vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

Analysis of immunity induced by the affinity-purified 21-kilodalton zygote-ookinete surface antigen of Plasmodium berghei

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.100

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2010.06.100

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39679346&oldid=1959299651"